Bottom line
XLV vs RXL: the short answer
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) and RXL (ProShares Ultra Health Care) share a meaningful slice of their top holdings — about 78% by weight.
XLV is cheaper at 0.08% vs 0.95% — a difference of $87 a year per $10,000 invested.
Over five years, XLV returned +8.1% a year vs +7.2% for RXL.
Updated Nov 19, 2026
XLV vs RXL side by side
| XLV | RXL | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | SPDR (State Street) | ProShares |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.08% | 0.95% |
| Annual cost per $10k | $8 | $95 |
| 10-yr cost on $10k (prospectus) | $103 | $1,305 |
| Max front load | None | None |
| 12b-1 fee | 0.02% | — |
| 1-yr return | +14.5% | +19.7% |
| 5-yr return (annualized) | +8.1% | +7.2% |
| 10-yr return (annualized) | +9.8% | +12.6% |
| Best quarter | +14.5% | +29.7% |
| Worst quarter | −12.7% | −28.9% |
| Net assets (fund) | $40.6B | $72.1M |
| Number of holdings | 65 | 70 |
| Portfolio turnover | 2% | 4% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | XLV | RXL | Difference |
|---|---|---|---|
| 2025 | +14.5% | +19.7% | −5.2% |
| 2024 | +2.5% | −2.7% | +5.2% |
| 2023 | +2.0% | −3.2% | +5.2% |
| 2022 | −2.1% | −15.1% | +13.1% |
| 2021 | +25.9% | +47.8% | −21.9% |
| 2020 | +13.3% | +19.2% | −6.0% |
| 2019 | +20.7% | +38.9% | −18.3% |
| 2018 | +6.3% | +5.4% | +0.9% |
| 2017 | +21.7% | +46.0% | −24.3% |
| 2016 | −2.8% | −8.9% | +6.1% |
Source: Fund prospectus bar charts
Holdings overlap
21 of XLV's top 25 holdings also appear in RXL's top 25.
| Holding | XLV | RXL |
|---|---|---|
| Eli Lilly & Co | 16.51% | 12.67% |
| Johnson & Johnson | 10.64% | 7.86% |
| AbbVie Inc | 7.74% | 5.57% |
| UnitedHealth Group Inc | 6.57% | 4.98% |
| Merck & Co Inc | 5.52% | 4.26% |
| Amgen Inc | 3.40% | 2.62% |
| Thermo Fisher Scientific Inc | 3.24% | 2.68% |
| Abbott Laboratories | 2.75% | 2.15% |
| Gilead Sciences Inc | 2.73% | 2.41% |
| Intuitive Surgical Inc | 2.45% | 2.18% |
| Pfizer Inc | 2.39% | 2.15% |
| CVS Health Corp | 2.30% | 1.67% |
| Vertex Pharmaceuticals Inc | 2.19% | 1.64% |
| Danaher Corp | 2.09% | 1.66% |
| Bristol-Myers Squibb Co | 2.05% | 1.68% |
Source: SEC Form N-PORT
XLV top 10
- Eli Lilly & Co — 16.51%
- Johnson & Johnson — 10.64%
- AbbVie Inc — 7.74%
- UnitedHealth Group Inc — 6.57%
- Merck & Co Inc — 5.52%
- Amgen Inc — 3.40%
- Thermo Fisher Scientific Inc — 3.24%
- Abbott Laboratories — 2.75%
- Gilead Sciences Inc — 2.73%
- Intuitive Surgical Inc — 2.45%
RXL top 10
- Eli Lilly & Co. — 12.67%
- ProShares GENIUS Money Market ETF — 11.81%
- Johnson & Johnson — 7.86%
- AbbVie, Inc. — 5.57%
- UnitedHealth Group, Inc. — 4.98%
- Merck & Co., Inc. — 4.26%
- Repurchase Agreement — 2.91%
- Thermo Fisher Scientific, Inc. — 2.68%
- Amgen, Inc. — 2.62%
- Gilead Sciences, Inc. — 2.41%
FAQ
What is the difference between XLV and RXL?
Which is cheaper, XLV or RXL?
Should I own both XLV and RXL?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.